NEWS

  • FineHeart makes Fierce Medtech’s 2018 List

    February 11, 2019

    February 11, 2019. FineHeart makes Fierce Medtech’s 2018 list of 15 exciting/innovative companies to watch. FierceMedTech’s Fierce 15 class of 2018 is aimed at advancement—whether it’s simpl...

    Read More
  • Broadview Ventures 2018 Annual Report

    February 6, 2019

    Broadview Ventures 2018 Annual Report...

    Read More
  • Vectorious Medical Technologies Announces World’s First In-Heart Microcomputer for Left Atrial Pressure Monitoring

    February 4, 2019

    Tel-Aviv, Israel (4 February, 2019) – Vectorious Medical Technologies, a medical device company enabling optimal management for heart failure patients, today announced the initiation of the VECTOR-H...

    Read More
  • Remedy Publication: Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial

    December 4, 2018

    Link to publication...

    Read More
  • ZZ Biotech Publication: Final Results of the RHAPSODY Trial

    November 9, 2018

    Link to publication...

    Read More
  • Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation

    November 5, 2018

    COPENHAGEN, Denmark — 5 November 2018: Acesion Pharma (“Acesion” or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhy...

    Read More
  • AtaCor Medical Raises $8.8M to Develop Substernal Cardiac Pacing System

    September 18, 2018

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. (www.atacor.com) announced today that it has completed a $8.8M Series A financing. Co-led by Boston-based Broadview Ventures and Israel-base...

    Read More
  • Aeromics Initiates Phase 1 Clinical Trial of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers

    July 10, 2018

    BRANFORD, Conn., July 9, 2018 /PRNewswire/ -- Aeromics, Inc. ("Aeromics" or "the Company"), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people af...

    Read More
  • CellAegis Announces Completion of Patient Enrollment in Danish Investigator Sponsored Clinical Trial Using autoRIC Device

    May 17, 2018

    TORONTO, Canada, May 17, 2018 – CellAegis Devices Inc. (“CellAegis” or the “Company”) a commercial-stage medical device company advancing innovative, non-invasive, safe and cost-effective so...

    Read More
  • CellAegis to complete enrollment in U.S. autoRIC trial by end of 2018

    May 8, 2018

    In addition to several large ongoing investigator-sponsored studies in Europe and Canada using its autoRIC device for automated remote ischemic conditioning (RIC), closely-held CellAegis Devices expec...

    Read More